CUSIP: 74365A309
Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
80,165,500
-
Total 13F shares
-
2,921,778
-
Share change
-
-1,495,829
-
Total reported value
-
$2,436,675
-
Put/Call ratio
-
106%
-
Price per share
-
$0.83
-
Number of holders
-
24
-
Value change
-
-$1,654,962
-
Number of buys
-
8
-
Number of sells
-
19
Quarterly Holders Quick Answers
What is CUSIP 74365A309?
CUSIP 74365A309 identifies PLX - Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2022
-
Previous quarter:
Q3 2021
Recent filing periods for CUSIP 74365A309:
Institutional Holders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) as of Q4 2021
As of 31 Dec 2021,
Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,921,778 shares.
The largest 10 holders included
MORGAN STANLEY, GROUP ONE TRADING, L.P., Phoenix Holdings Ltd., Spire Wealth Management, BlackRock Inc., TWO SIGMA ADVISERS, LP, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC, and COMMONWEALTH EQUITY SERVICES, LLC.
This page lists
25
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.